A clinical trial developed by a Taiwanese research team has offered a glimmer of hope for patients of neuroblastoma, a malignant cancer that appears in early childhood, a press statement released by the Academia Sinica said.
The research team at the research institute has proven that a combination of anti-cancer monoclonal antibodies (mAbs) with cytokines (natural hormones that help the immune system) is an effective anti-cancer therapy.
The new immunotherapy treatment pioneered by the research team, headed by Alice Yu (陳鈴津), deputy director of Academia Sinica’s Genomics Research Center, is the first study that confirms that immunotherapy is effective in improving cure rates for this childhood cancer, the statement said.
Yu, a pediatrician, has been working on the therapy for more than 20 years. She completed the Phase I and Phase II trials of this antibody at the University of California in San Diego.
The latest Phase III trial was sponsored by the US-based Children’s Oncology Group (COG), a cancer research organization, and the National Cancer Institute of the National Institutes of Health in the US. The latest results included children with neuroblastoma from many parts of the world.
Neuroblastoma is a malignant cancer occurring in early childhood in which the cancer cells arise from the nerve cells in the neck, chest or abdomen.
It is the most common cancer diagnosed in the first year of life and is responsible for 15 percent of cancer-related deaths in children.
The Phase III study showed that children with high risk neuroblastoma who received the new antibody-based immunotherapy (chimeric anti-GD2 antibody ch14.18) have a 20 percent better chance of living free of cancer, a significantly improved cure rate.
So far, Yu said, all US Federal Drug Administration (FDA) approved therapeutic anti-cancer mAbs or vaccines are directed against protein or glycoprotein antigens.
“The Phase III clinical trial is the first mAb targeting a glycolipid that has been shown to be effective,” Yu said.
More importantly, she added, this is the first study that proves that immunotherapy is effective in improving cure rates for this childhood cancer and her team is now focusing on making sure immunotherapy can be available to all children with this disease and on improving results.
COG Chairman Gregory Reaman stated in a press release that the clinical benefit of this approach against the notoriously stubborn child cancer is extraordinary and that the COG is anxious to continue its investigation to better define the toxicities and confirm its satisfactory risk-benefit ratio.
“We are hopeful that that this further study will result in commercialization and FDA approval and licensing of this experimental immunotherapeutic agent so that it can be made readily available as standard therapy to all children with this dreaded disease,” Reaman said in the statement.
Conventional treatment for the disease includes surgery, intensive chemotherapy with stem cell rescue (in which patients’ stem cells removed before treatment are returned after chemotherapy to repopulate the blood and immune system) and radiation therapy.
Despite these aggressive measures, only 30 percent of patients survive.
The immunotherapy evaluated in this study targets a specific glycolipid (sugar and fat) molecule on neuroblastoma cells called GD2 — which inhibits the immune system from attacking cancer cells — with an antibody called ch14.18.
This antibody binds to GD2 and provokes an attack by different types of immune cells against the cancer.
In her study, Yu and her colleagues compared the two-year event-free survival rate (the ratio of patients who were still alive and did not experience a recurrence) of 113 neuroblastoma patients who received the standard treatment (retinoic acid) plus the newly developed immunotherapy with 113 similar patients who only received the standard treatment.
The event-free survival rate for the immunotherapy group was 66 percent, compared to 46 percent for the standard treatment group. The most common side effects in the immunotherapy group were pain, vascular leak syndrome and allergic reactions.
As the study is the first effective immunotherapy reported for the disease and the first improvement on neuroblastoma cure rates of the last 10 years, it has drawn worldwide attention and was reported in USA Today and by US television network CBS.
It is estimated that it will take at least another two years to get FDA approval for the therapy.
An increase in Taiwanese boats using China-made automatic identification systems (AIS) could confuse coast guards patrolling waters off Taiwan’s southwest coast and become a loophole in the national security system, sources familiar with the matter said yesterday. Taiwan ADIZ, a Facebook page created by enthusiasts who monitor Chinese military activities in airspace and waters off Taiwan’s southwest coast, on Saturday identified what seemed to be a Chinese cargo container ship near Penghu County. The Coast Guard Administration went to the location after receiving the tip and found that it was a Taiwanese yacht, which had a Chinese AIS installed. Similar instances had also
GOOD DIPLOMACY: The KMT has maintained close contact with representative offices in Taiwan and had extended an invitation to Russia as well, the KMT said The Chinese Nationalist Party (KMT) would “appropriately handle” the fallout from an invitation it had extended to Russia’s representative to Taipei to attend its international banquet last month, KMT Chairman Eric Chu (朱立倫) said yesterday. US and EU representatives in Taiwan boycotted the event, and only later agreed to attend after the KMT rescinded its invitation to the Russian representative. The KMT has maintained long-term close contact with all representative offices and embassies in Taiwan, and had extended the invitation as a practice of good diplomacy, Chu said. “Some EU countries have expressed their opinions of Russia, and the KMT respects that,” he
VIGILANCE: The military is paying close attention to actions that might damage peace and stability in the region, the deputy minister of national defense said The People’s Republic of China (PRC) might consider initiating a hack on Taiwanese networks on May 20, the day of the inauguration ceremony of president-elect William Lai (賴清德), sources familiar with cross-strait issues said. While US Secretary of State Anthony Blinken’s statement of the US expectation “that all sides will conduct themselves with restraint and prudence in the period ahead” would prevent military actions by China, Beijing could still try to sabotage Taiwan’s inauguration ceremony, the source said. China might gain access to the video screens outside of the Presidential Office Building and display embarrassing messages from Beijing, such as congratulating Lai
Four China Coast Guard ships briefly sailed through prohibited waters near Kinmen County, Taipei said, urging Beijing to stop actions that endanger navigation safety. The Chinese ships entered waters south of Kinmen, 5km from the Chinese city of Xiamen, at about 3:30pm on Monday, the Coast Guard Administration said in a statement later the same day. The ships “sailed out of our prohibited and restricted waters” about an hour later, the agency said, urging Beijing to immediately stop “behavior that endangers navigation safety.” Ministry of National Defense spokesman Sun Li-fang (孫立方) yesterday told reporters that Taiwan would boost support to the Coast Guard